Likewise, it is relevant to assess whether different CD38 antibodies, such as daratumumab and isatuximab, are beneficial to use after a CD38-treatment pause and in which sequence, after which pause (3–6 months) and with which additional MM-agents they are pursued in clinical trials. The gene discussed is CD38; the disease is Miyoshi myopathy.